Erasca Revenue and Competitors

Location

$300M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Erasca's estimated annual revenue is currently $22.3M per year.(i)
  • Erasca's estimated revenue per employee is $140,377
  • Erasca's total funding is $300M.
  • Erasca's current valuation is $1.6B. (January 2022)

Employee Data

  • Erasca has 159 Employees.(i)
  • Erasca grew their employee count by -2% last year.

Erasca's People

NameTitleEmail/Phone
1
SVP Clinical DevelopmentReveal Email/Phone
2
VP Project Portfolio and Alliance ManagementReveal Email/Phone
3
VP, Head Clinical Pharmacology/DMPKReveal Email/Phone
4
VP FinanceReveal Email/Phone
5
VP ChemistryReveal Email/Phone
6
VP Portfolio and Program LeadershipReveal Email/Phone
7
VP Business DevelopmentReveal Email/Phone
8
General CounselReveal Email/Phone
9
VP Pharmaceutical Development and OperationsReveal Email/Phone
10
General Manager China & Senior Director, Global CollaborationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Erasca?

Our mission at Erasca is embedded in our name: To erase cancer in patients by creating a new generation of oncology drugs that we hope will not just treat, but actually cure. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncologyᅢᄁ¬ツᆲ¬トᄁs hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals.

keywords:N/A

$300M

Total Funding

159

Number of Employees

$22.3M

Revenue (est)

-2%

Employee Growth %

$1.6B

Valuation

N/A

Accelerator

Erasca News

2022-04-20 - Erasca (NASDAQ:ERAS) & Genmab A/S (NASDAQ:GMAB ...

Get Erasca alerts: This table compares Erasca and Genmab A/S's gross revenue, earnings per share and valuation.

2022-04-06 - Erasca To Host Investor Event with Leading KOL Dr. Scott ...

D., from MD Anderson Cancer Center, who will comment on therapeutic opportunities and Erasca's approach to targeting cancers driven by the RAS/...

2022-03-22 - Erasca Reports Fourth Quarter 2021 Financial Results and ...

At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering,...

2021-07-12 - Erasca, Inc. Prices IPO

Erasca, Inc. announced the initial public offering of 17,500,000 shares of its common stock on July 12. The common stock will be priced between $14.00 and $16.00 per share, according to Erasca’s Form S-1/A. Erasca, Inc. was founded in 2018 and is a clinical-stage precision oncology biotechnolog ...

2020-09-01 - Erasca Completes $36M Extension of Series B Financing

Erasca, a San Diego, CA-based cancer therapeutics company, completed a $36m extension of its Series B financing round, which brings the total round to $236m. This financing brings the total capital raised by the company to $300m. New investors include Partner Fund Management and OrbiMed. Erasc ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$21M159246%N/A
#2
$25.4M159-12%N/A
#3
$25.4M159-4%N/A
#4
$41.8M159-2%N/A
#5
$7.5M15910%N/A